Delta peritoneal cancer index (ΔPCI): A new dynamic prognostic parameter for survival in patients with colorectal peritoneal metastases

Eur J Surg Oncol. 2020 Apr;46(4 Pt A):590-599. doi: 10.1016/j.ejso.2019.11.515. Epub 2019 Nov 29.

Abstract

Background: The peritoneal cancer index (PCI) calculated during exploratory laparotomy is a strong prognostic factor for overall survival (OS) in patients with colorectal peritoneal metastases (PM) who undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC). Progression of the PCI between diagnostic laparoscopy (DLS) and potential CRS + HIPEC (ΔPCI) might be a more dynamic prognostic factor for OS after CRS + HIPEC.

Materials and methods: Between 2012 and 2018, all colorectal PM patients who underwent an exploratory laparotomy for potential CRS + HIPEC after DLS were retrospectively identified from a prospectively maintained database. Patients were divided into stable disease (ΔPCI 0-3), mild progression (ΔPCI 4-9), or severe progression (ΔPCI ≥10). Kaplan-Meier analysis and a multivariate Cox regression were performed.

Results: Eighty-four patients (ΔPCI 0-3, n = 35; ΔPCI 4-9, n = 34; and ΔPCI ≥10, n = 15) were analysed. Median OS after CRS + HIPEC was significantly decreased in patients with a ΔPCI of 4-9 (35.1 [95% CI 25.5-44.6]) or ΔPCI ≥10 (24.1 [95% CI 11.7-36.5]) compared to patients with a ΔPCI of 0-3 (47.9 [95% CI 40.0-55.7], p = 0.004). In multivariate regression analysis, ΔPCI remained an independent risk factor for OS: ΔPCI 4-9 HR 3.1 (95% CI 1.4-7.2, p = 0.007) and ΔPCI ≥10 HR 4.4 (95% CI 1.5-13.1, p = 0.007).

Conclusion: A high ΔPCI is an independent dynamic prognostic factor for OS and might reflect a more aggressive tumour biology in patients with colorectal PM. HIPEC surgeons should be aware of a high-ΔPCI-associated diminished prognosis and should reconsider CRS + HIPEC when confronted with a ΔPCI ≥10.

Keywords: Colorectal peritoneal metastases; Cytoreductive surgery; Diagnostic laparoscopy; Hyperthermic intraperitoneal chemotherapy; Overall survival; Peritoneal cancer index.

MeSH terms

  • Aged
  • Antibiotics, Antineoplastic / therapeutic use*
  • Carcinoma / secondary*
  • Carcinoma / therapy
  • Colorectal Neoplasms / pathology*
  • Cytoreduction Surgical Procedures
  • Disease Progression
  • Female
  • Humans
  • Hyperthermia, Induced
  • Kaplan-Meier Estimate
  • Laparotomy
  • Male
  • Middle Aged
  • Mitomycin / therapeutic use*
  • Peritoneal Neoplasms / secondary*
  • Peritoneal Neoplasms / therapy
  • Prognosis
  • Proportional Hazards Models
  • Survival Rate
  • Tumor Burden

Substances

  • Antibiotics, Antineoplastic
  • Mitomycin